[{"from": "human", "value": "What can you tell me about this molecule? [C][C][Branch1][C][C][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][Branch1][C][C][C][=Branch1][C][=O][O].[C][=C][Branch1][=C][N][=C][Branch1][Ring2][S][Ring1][Branch1][N][=C][Branch1][C][N][N][C][S][C][C][C][=Branch1][#Branch2][=N][S][=Branch1][C][=O][=Branch1][C][=O][N][N]"}, {"from": "gpt", "value": "The molecule is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine."}]